Skip to main content

Table 2 Differentially expressed canonical pathways (IPA) and upregulated KEGG pathways (GENECODIS) in ‘Good’ and ‘Bad’ PDAC

From: Molecular markers associated with outcome and metastasis in human pancreatic cancer

 

Goodversus control

Badversus control

Canonical pathways a

P-value

Upregulated genesc

P-value

Upregulated genesc

Integrin signalling

5.62E-7

RAC1, RAC2, ITGB4, ITGB5, ITGA6, ACTN1, MAP2K2, GSK3B, PPP1R12A, ARF1, ACTG2

4.79E-6

RAC1, ITGA2, ITGA3, ITGA6, ITGB1, ITGB4, ITGB5, ITGB6, ACTN1, ARF1

Ephrin receptor signalling

0.00002

RAC1, RAC2, EPHA2, EPHB2, EFNA4, EFNB2, MAP4K4, MAP2K2, STAT3, RHOA, ADAM10, VEGFA

0.00001

RAC1, EFNA5, EFNB2, EPHA2, EPHB4, STAT3, ADAM10, FGF1, VEGFA, PDGFC

Molecular mechanism of cancer

0.00063

RAC1, RAC2, CCND1, MAP2K2, TGFβ1, GSK3B, BRCA1, CDH1, BMP2, SMAD6, BAX, CTNNB1

  

P53 signalling

0.00089

TP53, PIK3C2A, RAC1, BAX, BIRC5, SERPINB5, GSK3B, BRCA1

0.02757

PRKDC, RAC1, BAX, CCND1, BIRC5, SERPINB5, CTNNB1, CDK2

Wnt/β-catenin

0.00550

RAC2, CSNK1A1, CSNK1E, SOX9, TGFβ1, SOX4, LRP5, CTNNB1, WNT10A

0.00323

CSNK1A1, TGFβ1, DKK1, DKK3, WNT5A, WNT10A, SOX4, SOX11, TCF7L2, TCF3

Pancreatic adenocarcinoma

  

0.00776

JAK1, RAC1, STAT3, CCND1, BIRC5, VEGF, TGFβ1, ERBB2, CDK2

PI3K/AKT Signaling

0.00933

RAC1, RAC2, JAK1, MAP2K2, PPP2R5

  

KEGG pathways b

    

P53 Signaling

2.20E-12

TP53, CDKN6, CCND1, CDK1, CDK2, SFN

3,03E-8

CDK1, CDK2, BAX, SERPINB5, CCND1, SFN

Wnt signalling

2,67E-07

WNT10A, CTNNB1, CTBP1, LRP5, TCF7L2, FZD8, GSK3B, PPP3R1, RAC1

0.00011

WNT5A, WNT10A, DKK1, DVL1, CTNNB1, CSNK1A1, CSNK1E, LRP5, RAC1, TCF7L2

Pancreatic cancer

3.00E-6

TGFβ1, RAC1, JAK1, VEGFA, ERBB2, STAT3,TP53, RAC2

0.00001

RAC1, TGFβ1, TGFα, VEGFA, ERBB2, STAT3, RAD51

NOTCH signalling

2.40E-6

JAG1, HES1, CTBP1, CTBP2, ADAM10

0.00012

DVL1, HES1, CTBP1, ADAM10

MAPK signalling

0.00015

FGFR2, TGFβ1, MAP2K5, MAP2K2, MAP2K3, MAP2K7, RAC1, DUSP10, DUSP3

  

Hedgehog signalling

0.00836

CSNK1E, BMP2, GSK3B, CSNK1A1

  
  1. aIPA was performed on respectively 2.806 (good) and 1.692 (bad) differentially expressed probe sets (with entry in the Ingenuity Knowledge Base; http://www.ingenuity.com). The most significant networks, functions and canonical pathways are listed.
  2. b KEGG analysis was performed on respectively 2.033 and 1.285 probesets upregulated in the good and bad PDAC samples using GENECODIS.
  3. c A selection of upregulated genes contributing to the pathways, is given.
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us